A case of ruptured epithelioid uterine leiomyosarcoma

Background: We report a rare case of epithelioid uterine leiomyosarcoma presenting with tumor rupture, a rare complication of uterine sarcomas. Case: The patient was a 47-year-old woman who was receiving filgotinib for ulcerative colitis and presented with genital bleeding. A uterine mass was detected, and malignancy was suspected. During the workup, she developed fever, genital bleeding, and lower abdominal pain and re-visited the emergency department. Coronavirus disease and intrauterine infections were suspected, and she was hospitalized. Despite antibiotic administration, no clinical improvement was observed. Computed tomography revealed irregular margins between the tumor and uterine muscle layer on the uterine fundus, raising strong suspicion of malignant tumor rupture. She was transferred to a tertiary care center and underwent total hysterectomy. Intraoperatively, the rupture site was covered by the omentum, and intra-abdominal spread of inflammation was limited. Histopathological examination revealed coagulative necrosis, proliferation of tumor cells with round nuclei, and numerous mitotic figures, leading to a diagnosis of epithelioid uterine leiomyosarcoma. Local recurrence at the vaginal stump was observed 10 months postoperatively, and treatment is ongoing. Conclusions: In this case, the diagnosis was triggered by genital bleeding. During evaluation, tumor rupture occurred, but clinical symptoms were minimal due to coverage of the rupture site by the omentum, making diagnosis challenging. Thorough screening for malignancy and careful monitoring are essential when using Janus kinase inhibitors.

Epithelioid uterine leiomyosarcoma; Rupture; Filgotinib; COVID-19

[1] Yang Q, Madueke-Laveaux OS, Cun H, Wlodarczyk M, Garcia N, Carvalho KC, et al. Comprehensive review of uterine leiomyosarcoma: pathogenesis, diagnosis, prognosis, and targeted therapy. Cells. 2024; 13: 1106.

[2] Giannini A, D’Augè TG, Bogani G, Laganà AS, Chiantera V, Vizza E, et al. Uterine sarcomas: a critical review of the literature. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2023; 287: 166–170.

[3] Hasanzadeh M, Loyen AH, Fathabad MN, Roshan NM, Moloudian M. Severe hemoperitoneum: spontaneous rupture of uterine leiomyosarcoma: a rare case. Journal of Obstetrics, Gynecology and Cancer Research. 2025; 10: 727–732.

[4] Codispoti N, Xu J, Montemorano L, Sadowski EA, Kushner DM, Weisman PS. A case of CDKN2C/CIC null epithelioid leiomyosarcoma with a low-grade component indistinguishable from leiomyoma. International Journal of Gynecological Pathology. 2025; 44: 541–546.

[5] Kajiyama H, Tamauchi S, Takahashi F, Kawana K; Board members of the 2023 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: annual patient report for 2021 and annual treatment report for 2016. Journal of Obstetrics and Gynaecology Research. 2025; 51: e16168.

[6] Chapel DB, Nucci MR, Quade BJ, Parra-Herran C. Epithelioid leiomyosarcoma of the uterus. The American Journal of Surgical Pathology. 2022; 46: 464–475.

[7] International Agency for Research on Cancer. World Health Organization classification of tumours of the female reproductive organs. 5th edn. IARC: Lyon. 2020.

[8] Katsakhyan L, Shahi M, Eugene HC, Nonogaki H, Gross JM, Nucci MR, et al. Uterine leiomyosarcoma associated with perivascular epithelioid cell tumor: a phenomenon of differentiation/dedifferentiation and evidence suggesting cell-of-origin. The American Journal of Surgical Pathology. 2024; 48: 761–772.

[9] Hicks G, McCallum IJ, Ogah K, Guirguis M, Kasaraneni R. Spontaneous uterine perforation secondary to uterine leiomyosarcoma presenting as acute abdomen with haemoperitoneum. Journal of Obstetrics and Gynaecology. 2010; 30: 211–212.

[10] Oda H, Hirakawa H. Spontaneous rupture of uterine smooth muscle tumour presenting acute abdominal pain and haemoperitoneum. BMJ Case Reports. 2018; 2018: bcr2017222806.

[11] Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecologic Oncology. 2017; 145: 208–216.

[12] Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Frontiers in Immunology. 2021; 18: 253–261.

[13] Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews. 2019; 18: 102390.

[14] Song YK, Kim J, Park S, Kwon JW. Potential adverse events reported with the Janus kinase inhibitors approved for the treatment of rheumatoid arthritis using spontaneous reports and online patient reviews. Frontiers in Pharmacology. 2021; 12: 792877.

[15] RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. The Lancet. 2022; 400: 359–368.

[16] Capochiani E, Frediani B, Iervasi G, Paolicchi A, Sani S, Roncucci P, et al. Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease: analysis of data collection from RESPIRE protocol. Frontiers in Medicine. 2020; 7: 466.

[17] Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. The New England Journal of Medicine. 2022; 386: 316–326.

[18] Chen Z, Zheng X, Zeng W, Wang J, Lin Q. JAK2 inactivating mutations promotes endometrial cancer progression by targeting HIF-1α. Discover Oncology. 2024; 15: 836.

[19] Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, et al. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer. 2014; 14: 317.

[20] Yan S, Li Z, Thiele CJ. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in neuroblastoma and pediatric sarcomas in vitro and in vivo. Oncotarget. 2013; 4: 433–445.